Embla Medical Q4 and Full Year 2025 Financial Overview
Embla Medical hf has released its interim report for the fourth quarter and full year 2025, revealing solid sales performance and optimism for the future. According to Sveinn Sölvason, President and CEO, the company achieved impressive sales of USD 257 million in the fourth quarter, reflecting a notable 7% organic growth. In local currency, the organic sales growth increased to 10%, bolstered by the majority investment in Streifeneder ortho.production, which was finalized in September 2025.
Performance Highlights
In the fourth quarter, Embla Medical experienced substantial growth, driven particularly by its Prosthetics & Neuro Orthotics (P&NO) division. This segment exhibited strong momentum across EMEA, supported by innovative product launches. The Patient Care segment also showed positive recovery during Q4, while sales in the Bracing & Supports category remained stable.
Q4 2025 Key Figures
The EBITDA margin stood at 19%, a slight decrease from 21% in the same quarter the previous year. Despite the positive market growth and improved manufacturing efficiency, the margin was adversely affected by fluctuations in currency exchange rates, tariffs, and initiatives aimed at enhancing long-term viability in the Patient Care sector.
2025 Financial Summary
Throughout the entirety of 2025, Embla Medical made notable strides. The company recorded organic sales growth of 6% for the full year. The sales evolution was primarily attributed to the P&NO segment, which achieved a 10% organic growth, while Bracing & Supports sales saw a minor decline of 1%.
Gross Profit and EBITDA
Gross profit was reported at USD 158 million with a consistent gross profit margin of 62% across both Q4 and the full year 2025. However, this figure was marginally lower at 63% in Q4 2024. The company reported an EBITDA of USD 48 million, yielding a 20% margin for the full year, matching the prior year's results. The decline in gross profit margin and other implications from foreign exchange rates and tariffs impacted the overall EBITDA margin.
Net Profit and Free Cash Flow
In terms of profitability, net profit surged by 33% to USD 25 million in Q4, translating to a net profit margin of 10%. For the full year, net profit saw an increase of 21%. Free cash flow also improved significantly, reaching USD 100 million, which represented 11% of total sales, up from 9% in the preceding year.
Debt Ratios
At the conclusion of Q4 2025, the net interest-bearing debt (NIBD) to EBITDA before special items was maintained at 2.4x, consistent with levels from Q4 2024 and aligning with the target ratio of 2-3x EBITDA.
Embla Medical's Sustainable Growth Initiatives
Embla Medical has been recognized for its commitment to sustainable practices, ranking among the top 500 companies globally. This is the second consecutive year that Embla has been acknowledged for excellence in sustainable growth. Furthermore, in late 2025, the company announced the establishment of a new prosthetic clinic in Kyiv, along with a partnership with the Government of Iceland. This initiative aims to provide high-quality prosthetic care to up to 1,000 Turkish patients, enhancing mobility and rehabilitation efforts.
Looking Ahead: 2026 Guidance
The company has set an optimistic outlook for 2026, projecting organic sales growth of 5-8%. This growth is anticipated to be driven by robust volume increases in the core business alongside moderate price adjustments. Additionally, the EBITDA margin guidance is anticipated to fall between 20% and 22%, supported by operational scaling and strict cost control measures.
Frequently Asked Questions
What were the key financial highlights for Q4 2025?
Embla Medical reported sales of USD 257 million in Q4 2025, with a 7% organic growth. The EBITDA margin was 19%, reflecting solid market performance.
How did the pandemic impact Embla Medical's sales growth?
Despite challenges, Embla Medical witnessed healthy growth driven mainly by its Prosthetics & Neuro Orthotics segment, as demand for medical solutions surged during the pandemic.
What are the projections for 2026?
Embla Medical has set guidance for a 5-8% organic sales growth and anticipates an EBITDA margin of 20-22%, boosted by efficiency and emphasis on cost control.
What sustainability initiatives has Embla Medical undertaken?
Embla Medical has been recognized for its sustainable practices and recently initiated a project to provide prosthetic care in Ukraine, highlighting its commitment to social responsibility.
How does Embla Medical ensure financial health?
The company maintains a cautious approach to and has balanced debt management, with a consistent NIBD to EBITDA ratio, ensuring financial stability.
